Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non-Current Deffered Revenue: 2013-2016

Historic Non-Current Deffered Revenue for Amphastar Pharmaceuticals (AMPH) over the last 4 years, with Dec 2016 value amounting to $97,000.

  • Amphastar Pharmaceuticals' Non-Current Deffered Revenue rose 623.21% to $1.2 million in Q3 2017 from the same period last year, while for Sep 2017 it was $1.2 million, marking a year-over-year increase of 623.21%. This contributed to the annual value of $97,000 for FY2016, which is 92.76% down from last year.
  • As of FY2016, Amphastar Pharmaceuticals' Non-Current Deffered Revenue stood at $97,000, which was down 92.76% from $1.3 million recorded in FY2015.
  • In the past 5 years, Amphastar Pharmaceuticals' Non-Current Deffered Revenue ranged from a high of $2.6 million in FY2013 and a low of $97,000 during FY2016.
  • For the 3-year period, Amphastar Pharmaceuticals' Non-Current Deffered Revenue averaged around $1.1 million, with its median value being $1.3 million (2015).
  • Data for Amphastar Pharmaceuticals' Non-Current Deffered Revenue shows a maximum YoY slumped of 92.76% (in 2016) over the last 5 years.
  • Yearly analysis of 4 years shows Amphastar Pharmaceuticals' Non-Current Deffered Revenue stood at $2.6 million in 2013, then fell by 24.50% to $2.0 million in 2014, then tumbled by 32.44% to $1.3 million in 2015, then slumped by 92.76% to $97,000 in 2016.